Master the MRCP pancreas protocol: heavy T2 sequences, negative oral contrast timing, duodenal fluid overlap fixes, top 10 pathologies, and a complete pitfall framework for radiographers and radiologists.

Pancreas MRCP Protocol: 10 Critical Steps for Duct Visualization

Creator: SATMED Health
Published: 2026-07-08

Day 12 of 30 · Hepatobiliary & Pancreatic Imaging 🕒 42 min read ✔ Medically Reviewed

At a Glance

Sequences Used

Heavy T2-weighted 3D thin-slab MRCP (TE > 600 ms)
2D thick-slab single-shot projections (multi-angle)
Axial/coronal T2 HASTE of the upper abdomen
Axial in/out-of-phase and fat-suppressed T1 GRE
Diffusion-weighted imaging (b = 0, 400, 800 s/mm²)

Contrast Protocol

None for the routine, non-contrast MRCP pancreas protocol. A gadolinium-based dynamic post-contrast series is added only when a solid mass, main-duct IPMN, or malignancy is suspected on the initial heavy-T2 series.

Artefact Reduction Techniques

Negative oral contrast agent 15 minutes pre-scan
Extended fasting (4–6 hours) to reduce duodenal fluid
Respiratory triggering or breath-hold acquisition
Fat saturation and high-bandwidth acquisition

Key Pitfalls

Radiographers: duodenal fluid overlap obscuring the ampulla
Radiologists: pseudo-filling defects mimicking distal CBD stones
Physicians: mistaking normal duct caliber for obstruction

Introduction to the pancreas MRCP protocol

The MRCP pancreas protocol is a non-invasive, contrast-free technique that exploits the intrinsically long T2 relaxation time of static or slow-moving fluid to generate a projection map of the pancreatic duct, common bile duct, and intrahepatic biliary radicles. Unlike endoscopic retrograde cholangiopancreatography (ERCP), MRCP carries no procedural risk of pancreatitis, perforation, or bleeding, which has made it the first-line study for suspected choledocholithiasis, pancreatic divisum, chronic pancreatitis, and ductal strictures.

Clinical context The pancreatic duct (duct of Wirsung) and the accessory duct (duct of Santorini) are frequently only a few millimetres in caliber, so image quality in this protocol is disproportionately sensitive to motion, bowel fluid, and susceptibility effects. A technically imperfect heavy-T2 acquisition can convincingly mimic — or conceal — a genuine filling defect, making radiographer technique and radiologist pattern recognition equally decisive to diagnostic accuracy.

This article works through the full non-contrast MRCP pancreas protocol from anatomy to acquisition parameters, walks through the ten most clinically significant pancreaticobiliary pathologies, and builds a three-tier pitfall framework spanning the scanning bay, the reading room, and the referring physician’s clinic.

Anatomy of the pancreas and biliary tree

The pancreas is a retroperitoneal gland divided into head, uncinate process, neck, body, and tail. The head sits within the C-loop of the duodenum and is intimately related to the distal common bile duct (CBD), which usually courses through or immediately posterior to the pancreatic head before joining the main pancreatic duct at the ampulla of Vater. The neck overlies the superior mesenteric vein, the body crosses anterior to the splenic vein and aorta, and the tail extends into the splenic hilum.

The main pancreatic duct (duct of Wirsung) runs the length of the gland, receiving 15–20 short side branches, and normally measures 2–3 mm in the body, tapering slightly toward the tail. In roughly 60–70% of individuals it fuses with the CBD to form a short common channel before draining through the major papilla; in the remainder, separate or juxtaposed openings exist. The accessory duct (duct of Santorini) drains the uncinate process and superior pancreatic head and opens through the minor papilla, proximal and slightly superior to the major papilla — the ductal configuration relevant to pancreatic divisum.

Biliary tree relations

The extrahepatic biliary system — right and left hepatic ducts, common hepatic duct, cystic duct, gallbladder, and CBD — is imaged in the same acquisition. The CBD is conventionally divided into supraduodenal, retroduodenal, pancreatic, and intramural (ampullary) segments; the pancreatic and intramural segments are the most common sites for impacted stones and are also the segments most vulnerable to the duodenal fluid overlap artefact discussed later in this article.

Vascular and nodal landmarks

The splenic artery courses along the superior border of the body and tail; the gastroduodenal artery marks the anterolateral head; the superior mesenteric artery and vein pass posterior to the neck. Peripancreatic and portahepatic lymph node stations are routinely assessed on the axial T2 and DWI series acquired alongside the MRCP sequences, since nodal involvement materially changes staging in suspected malignancy.

🫀

Standardize hepatobiliary MRI workflow across your department

See how SATMED Health’s imaging consumables support consistent, artifact-free abdominal MRI protocols.

Explore Abdominal MRI Solutions →

MR tissue relaxation values

Heavy T2-weighted MRCP sequences are built entirely around the relaxation-time contrast between static fluid (very long T2) and background soft tissue (short-to-intermediate T2). The table below lists representative relaxation values for the structures relevant to the pancreaticobiliary anatomy described above.

Tissue / Structure	T1 (ms) @ 1.5T	T2 (ms) @ 1.5T	T1 (ms) @ 3.0T	T2 (ms) @ 3.0T
Bile / pancreatic duct fluid (static)	2500–3000	700–1400	2900–3300	650–1200
Pancreatic parenchyma (normal)	500–580	40–55	650–750	35–48
Liver parenchyma	500–550	40–50	800–900	34–46
Spleen	1000–1100	70–80	1300–1400	60–75
Renal cortex	950–1050	55–65	1200–1300	50–60
Retroperitoneal fat	200–250	60–80	250–300	55–75
Duodenal/gastric fluid (mobile)	2400–2900	500–1200	2800–3200	450–1000
Skeletal muscle	860–900	40–45	1400–1450	35–40

Because static bile and pancreatic secretions have a T2 roughly an order of magnitude longer than surrounding parenchyma, an echo time above 600 ms all but eliminates signal from solid tissue while preserving strong signal from ductal fluid — the physical basis of the entire heavy T2-w MRCP acquisition. Critically, gastric and duodenal fluid share almost identical T2 values with ductal fluid, which is precisely why they cannot be distinguished by contrast alone and must instead be managed with negative oral contrast and fasting protocols.

Scanning technique — 10 steps

Patient preparation and fasting. Instruct at least 4–6 hours of fasting to reduce gastric and duodenal fluid volume and to promote gallbladder distension, which improves cystic duct and CBD conspicuity.
Administer negative oral contrast. Give a negative oral contrast agent (e.g., dilute pineapple or blueberry juice, or a proprietary superparamagnetic iron oxide suspension) approximately 15 minutes before the scan to suppress high-signal fluid in the stomach and duodenum.
Coil selection and positioning. Position the patient supine, feet-first, using a torso phased-array coil centered over the epigastrium at the level of the xiphoid process.
Localizer and shim. Acquire triplanar localizers; perform a dedicated local shim over the pancreaticobiliary region to minimize susceptibility-induced signal loss near the duodenal air-fluid interface.
Coronal 2D thick-slab MRCP. Acquire a single-shot heavy T2-w thick-slab (40–70 mm) projection in the coronal plane, oblique to the expected duct axis, repeated at 2–3 rotating angles to overcome overlapping structures.
3D thin-slab MRCP. Acquire a respiratory-triggered or navigator-gated 3D turbo/fast spin-echo heavy T2-w volume (0.8–1.2 mm isotropic, TE > 600 ms) for source-image review and multiplanar reformats.
Axial and coronal T2 HASTE. Acquire breath-hold single-shot T2 HASTE of the upper abdomen to assess parenchyma, peripancreatic fluid, and adjacent organs.
Axial in/out-of-phase and fat-saturated T1. Acquire dual-echo GRE for fat content assessment and fat-saturated T1 to evaluate parenchymal signal and detect hemorrhagic pancreatitis or fat necrosis.
Diffusion-weighted imaging. Acquire free-breathing DWI (b = 0, 400, 800 s/mm²) with ADC map generation to characterize solid lesions and inflammatory changes.
Quality review and targeted re-acquisition. Review thick-slab and 3D source images at the console for duodenal fluid overlap or motion; repeat the affected angle or apply an additional spatial saturation band before the patient leaves the scanner.

Scanner comparison: 1.5T vs 3.0T for MRCP

Parameter	1.5T	3.0T
Baseline SNR	Adequate; standard workhorse field strength	~2× higher intrinsic SNR, enabling thinner slices
T2 of bile/duct fluid	Slightly longer T2	Slightly shorter T2 but higher SNR compensates
Susceptibility artifact (bowel gas)	Lower	Higher — more prone to duct signal dropout near duodenum
SAR / RF heating	Lower — long TSE trains are easier to run	Higher — requires TR extension or reduced refocusing flip angle
Chemical shift / fat suppression	Less robust; may need STIR	More robust spectral fat-sat, though more inhomogeneous
Recommended use case	General screening MRCP, body habitus concerns	Small side-branch IPMN detection, subtle stricture characterization

Contrast media protocol

The routine MRCP pancreas protocol described in this article is non-contrast. Diagnostic duct visualization depends purely on the intrinsic long-T2 signal of static fluid, and gadolinium administration does not improve ductal conspicuity on the heavy T2-w sequences — it can, in fact, add cost, time, and unnecessary patient risk without diagnostic benefit for duct-focused indications such as suspected choledocholithiasis or pancreatic divisum.

Safety rationale Reserving contrast administration for cases with a genuine indication reduces cumulative gadolinium exposure, shortens table time, and avoids unnecessary intravenous access — particularly relevant in patients with chronic pancreatitis who may already have compromised renal function from recurrent dehydration or diabetes.

A dynamic contrast-enhanced series is added when the non-contrast heavy T2-w images reveal a mass, an abrupt “duct cut-off” sign, main-duct or mixed-type IPMN, or asymmetric ductal dilatation suspicious for malignancy. In these cases, a standard extracellular gadolinium-based contrast agent is administered as follows: 10–15 mL (0.1 mmol/kg) injected at 2.0–3.0 mL/s, followed by a 100 mL saline chaser at the same flow rate, with fat-suppressed 3D T1 GRE acquisitions obtained in arterial (18–20 s), portal venous (60–70 s), and delayed (3 minute) phases to characterize enhancement pattern, capsular integrity, and vascular involvement.

💉

Consistent, air-free contrast delivery when it’s indicated

Reliable injection systems matter most on the cases where contrast findings change the diagnosis.

Explore Contrast Delivery Solutions →

Specific absorption rate

Heavy T2-weighted MRCP sequences rely on long echo trains of closely spaced 180° refocusing pulses, which makes them among the highest-SAR acquisitions in a routine abdominal MRI protocol — a consideration that becomes more pressing at 3.0T, where RF power deposition scales approximately with the square of field strength.

Sequence	Typical whole-body SAR	Field strength	Regulatory limit reference
3D heavy T2-w MRCP (thin-slab)	1.2–1.8 W/kg	1.5T	ICRP / IEC normal operating mode
3D heavy T2-w MRCP (thin-slab)	2.0–2.8 W/kg	3.0T	IEC first-level controlled mode
2D thick-slab single-shot	0.6–1.0 W/kg	1.5T / 3.0T	Normal operating mode
Axial T2 HASTE	0.8–1.4 W/kg	1.5T / 3.0T	Normal operating mode

Five dose-reduction strategies

Reduce refocusing flip angle using variable flip-angle (VFA) echo trains — a proven technique that lowers SAR by up to 60% with minimal loss of duct-to-background contrast, aligned with ICRP as-low-as-reasonably-achievable principles.
Extend TR modestly on 3.0T acquisitions to allow additional inter-pulse cooling time without materially lengthening the overall breath-hold or navigator window.
Apply parallel imaging acceleration to shorten the echo train length per excitation, directly reducing cumulative RF energy deposition — see the parallel imaging section below.
Use vendor SAR-monitoring feedback at the console in real time and select the “normal operating mode” ceiling per IEC 60601-2-33, consistent with AAPM MR safety guidance.
Segment the acquisition into shorter respiratory-triggered blocks rather than one continuous long echo train, distributing RF deposition over a longer real-world time window and staying within EC Radiation Protection 185 recommended practice for MR safety governance.

Top 10 pathologies

Choledocholithiasis

Stone: T2 signal void; bile: T2 hyperintense (700–1400 ms)

Heavy T2-w thin-slab is essential — negative oral contrast prevents duodenal fluid from mimicking a distal stone.

Pancreatic divisum

Duct fluid T2 700–1400 ms; dorsal duct crosses CBD anteriorly

Requires thin coronal-oblique reformats through the minor papilla; thick-slab alone often misses the crossing sign.

Side-branch IPMN

Cystic fluid T2 > 600 ms; T1 hypointense unless proteinaceous

3D isotropic thin-slab needed to demonstrate ductal communication, the defining diagnostic criterion.

Main-duct IPMN

Diffusely dilated duct > 5–10 mm, T2 hyperintense

Prompts addition of post-contrast dynamic series to assess for mural nodularity and malignant transformation.

Chronic pancreatitis

Parenchyma T1 signal loss (fibrosis); duct beading, T2 hyperintense

Secretin-enhanced dynamic MRCP (where available) improves side-branch and exocrine reserve assessment.

Acute pancreatitis

Peripancreatic fluid T2 markedly hyperintense; parenchymal edema

Fat-saturated T1 detects hemorrhagic necrosis; DWI helps identify infected/necrotic collections.

Pancreatic ductal adenocarcinoma

Mass T1 hypointense, T2 mildly hyperintense; “double duct” sign

Abrupt duct cut-off on MRCP triggers mandatory post-contrast dynamic imaging and DWI restriction assessment.

Ampullary tumor

T2 intermediate signal at ampulla; dilated CBD and PD (“double duct”)

Requires thin-slice oblique-coronal imaging through the ampulla to avoid duodenal fluid obscuring the lesion.

Primary sclerosing cholangitis

Multifocal strictures/beading, T2 hyperintense skip lesions

Full intrahepatic biliary tree coverage on 3D MRCP is critical — thick-slab alone under-detects peripheral strictures.

Autoimmune pancreatitis

Diffuse “sausage-shaped” gland, T2 mildly hyperintense; capsule-like rim

Diffuse narrowing of the main duct without upstream dilatation helps distinguish it from adenocarcinoma on MRCP.

🔬

Confident characterization from screening to staging

Explore SATMED Health resources supporting consistent hepatobiliary and pancreatic MRI throughput.

Explore Pancreaticobiliary Solutions →

Pitfalls — radiographers

Primary scanning pitfall: Duodenal fluid overlap. Retained gastric and duodenal fluid shares near-identical T2 relaxation characteristics with bile and pancreatic duct fluid, and when not suppressed it directly overlaps the ampullary and distal CBD region — precisely where small stones and ampullary tumors are most clinically significant and most easily missed or falsely suggested.

Category	Description	Mitigation
Duodenal fluid overlap	Retained gastric/duodenal fluid mimics or obscures distal CBD/ampullary pathology on thick-slab projections	Administer negative oral contrast (e.g., pineapple juice) 15 minutes pre-scan; confirm adequate fasting interval
Respiratory motion blur	Free-breathing 3D acquisitions ghost or blur fine duct detail	Use respiratory triggering/navigator gating or convert to a segmented breath-hold protocol
Incomplete slab coverage	Thick-slab angle fails to capture the full ductal course, especially at the ampulla or intrahepatic radicles	Acquire 2–3 rotating oblique-coronal angles per protocol step 5
Susceptibility signal dropout	Adjacent bowel gas causes local field inhomogeneity and duct signal loss	Perform a dedicated local shim; consider repositioning or a brief delay for gas migration
Suboptimal fat suppression	Incomplete fat-sat on axial T1 GRE reduces conspicuity of small parenchymal lesions	Verify shim quality; use Dixon-based fat-water separation where available

Pitfalls — radiologists

Primary interpretation pitfall: Pseudo-filling defect from duodenal fluid mimicking a distal CBD stone. When the technical mitigation above is incomplete, an interpreting radiologist unfamiliar with this artefact can misread residual duodenal fluid signal as a true intraluminal filling defect at the ampulla — the exact inverse error of missing a genuine small stone obscured by the same fluid.

Pitfall	Mechanism	Consequence	Mitigation
Pseudo-filling defect from duodenal fluid	Overlapping high-T2 fluid signal projects onto the distal CBD on thick-slab MIP images	False-positive choledocholithiasis; unnecessary ERCP referral	Always correlate with thin-slab 3D source images and axial HASTE before calling a distal CBD stone
Pneumobilia mimicking stones	Air within the biliary tree produces signal voids resembling calculi	False-positive stone diagnosis	Check for dependent, non-gravitating position and correlate with prior biliary intervention history
Side-branch IPMN overcall	Any T2-hyperintense cystic focus near the duct is presumed to be IPMN without confirming ductal communication	Overdiagnosis and unnecessary surveillance burden	Demonstrate direct communication with the main duct on thin-slab source images before labeling as IPMN
Partial volume averaging of small stones	Sub-3 mm calculi are smoothed out on thick-slab MIP reconstructions	False-negative for clinically significant microlithiasis	Review thin-slab source images at native resolution, not only the projection MIP
Chronic pancreatitis vs. adenocarcinoma confusion	Both cause duct narrowing and upstream dilatation on MRCP alone	Delayed cancer diagnosis or unnecessary resection anxiety	Assess for abrupt vs. tapered cut-off and add post-contrast dynamic imaging when uncertain

Pitfalls — non-radiology physicians

Pitfall	What they see	What it actually is	Clinical danger	What to do
“Filling defect” on the report	A stated filling defect at the distal CBD	May be a technical duodenal fluid artefact, not a true stone	Unnecessary ERCP with associated pancreatitis/perforation risk	Discuss the finding directly with radiology before scheduling an invasive procedure
Normal-caliber duct assumed benign	A pancreatic duct reported as normal caliber	Early adenocarcinoma can present with subtle, non-dilating duct narrowing	False reassurance in a patient with concerning symptoms	Correlate imaging with CA 19-9, weight loss, and new-onset diabetes; consider follow-up imaging
“Cyst” terminology	A pancreatic “cyst” mentioned in the report	Side-branch IPMN, pseudocyst, and true cyst all use overlapping language but carry very different management pathways	Inappropriate surveillance interval or missed malignant potential	Request the specific cystic lesion subtype and any ductal communication findings from radiology
No contrast administered	A “non-contrast” MRI report for a patient with a known mass	Routine MRCP is intentionally non-contrast; a mass finding should trigger a follow-up contrast-enhanced series, not alarm about an incomplete study	Confusion or unnecessary repeat imaging request	Confirm with radiology whether the non-contrast findings already warrant an added dynamic contrast series
Divisum labeled “anomaly”	Pancreatic divisum described as an anatomic variant	Usually asymptomatic and clinically silent unless recurrent pancreatitis is present	Unwarranted patient anxiety or inappropriate intervention referral	Correlate with clinical history of recurrent idiopathic pancreatitis before referring for sphincterotomy

🩺

Bridge the gap between imaging and the clinic

Discover how SATMED Health supports multidisciplinary hepatobiliary imaging workflows.

Explore Clinical Workflow Solutions →

Pitfall comparison summary

🟡 Scanning (radiographers)

Duodenal fluid overlap
Respiratory motion blur
Incomplete slab coverage
Susceptibility dropout

🔴 Interpretation (radiologists)

Pseudo-filling defect from fluid
Pneumobilia mimicking stones
Side-branch IPMN overcall
Small stone partial volume loss

🟣 Clinical (physicians)

Over-trusting “filling defect” language
False reassurance from normal caliber
Cyst terminology confusion
Misreading intentional non-contrast study

AI and automation

Deep learning reconstruction is increasingly used to accelerate heavy T2-w MRCP acquisitions, denoising undersampled k-space data to shorten breath-hold or navigator windows without sacrificing duct conspicuity — directly reducing the exposure window to the motion and susceptibility pitfalls described above. Several FDA-cleared and CE-marked deep-learning reconstruction platforms are now integrated into commercial MR consoles for abdominal and MRCP-specific acquisitions, alongside automated duct-segmentation tools that flag caliber changes and abrupt cut-offs for radiologist review.

These tools function as a second-reader aid rather than a replacement for source-image correlation — the pseudo-filling-defect pitfall above remains a human-judgment problem that automated segmentation alone does not resolve, since the algorithm can be fooled by the same overlapping fluid signal as the interpreting radiologist unless the underlying acquisition was properly prepared.

🤖

Bring AI-ready acquisition quality to every MRCP study

Consistent, artifact-minimized source images are the foundation every AI reconstruction and segmentation tool depends on.

Explore AI-Ready Imaging Solutions →

Reducing artefacts with patients and parameters

Beyond the MRCP-specific fixes above, four categories of scanning parameters govern image quality across every MRI protocol, including this one, and are worth understanding as a unified framework.

1. Spatial resolution

Matrix size (frequency × phase) increases spatial resolution as it grows, but decreases SNR because each voxel becomes smaller. Field of view (FOV) works the same way in reverse: reducing FOV increases spatial resolution but again shrinks voxel size and reduces SNR. Slice thickness follows the identical trade-off — thinner slices improve resolution and reduce partial volume averaging (directly relevant to the small-stone pitfall above) but significantly decrease SNR.

2. Signal-to-noise ratio (SNR)

SNR is the strength of diagnostic signal relative to background noise; low SNR produces grainy images that obscure fine duct detail. Number of averages (NEX/NSA) improves SNR by acquiring data multiple times, but doubling the averages roughly doubles scan time. Receiver bandwidth reduction limits recorded noise and boosts SNR, at the cost of longer scan times and increased chemical shift artifact. Coil selection — a dedicated torso phased-array coil rather than a whole-body coil — captures a substantially stronger signal from the pancreaticobiliary region.

3. Image contrast

Repetition time (TR) is the interval between RF pulses; a short TR maximizes T1 contrast while a long TR minimizes it. Echo time (TE) is the interval between the RF pulse and echo peak — a short TE minimizes T2 effects, while the very long TE (>600 ms) used throughout this MRCP protocol maximizes T2 weighting so fluid-filled ducts appear maximally bright. Flip angle controls proton excitation and is especially critical in the gradient-echo sequences used for parenchymal and post-contrast imaging.

4. Artifact control

Phase encoding direction can be swapped to shift motion-induced artifact away from the ductal region of interest. Flow compensation and respiratory gating use physiological triggers to minimize blurring and ghosting from pulsatile or respiratory motion — the primary defense against the motion-blur pitfall described above. Parallel imaging uses multiple coil elements simultaneously to reduce phase-encoding steps, cutting scan time and reducing motion sensitivity, and is discussed in full in the next section.

Parallel imaging protocols and parameters

Parallel imaging acceleration is particularly valuable in MRCP because it shortens the echo train per excitation, directly reducing both SAR (see above) and the motion-sensitivity window during 3D thin-slab acquisition. The turbo factor — the number of k-space lines acquired per excitation in a turbo/fast spin-echo sequence — must be balanced against blurring, SAR, and effective TE.

Parameter	1.5T recommendation	3.0T recommendation
Turbo factor (low, ~15–25)	Sharper duct edges; higher SAR; use for thin-slab detail sequences	Rarely used alone — SAR too high without acceleration; pair with parallel imaging factor ≥2
Turbo factor (moderate, ~30–60)	Standard balance for routine 3D MRCP	Standard with parallel imaging factor 2 to control SAR and blurring
Turbo factor (high, >80)	Used for rapid thick-slab single-shot only; some duct-edge blurring accepted	Used for single-shot thick-slab; requires reduced refocusing flip angle (VFA) to stay within SAR limits
Parallel imaging acceleration factor	1.5–2 typically sufficient given lower baseline SAR	2–3 recommended to offset higher SAR and enable thinner isotropic voxels
Effective TE management	Standard k-space centric ordering, TE > 600 ms achievable with moderate turbo factor	May need to prioritize k-space center earlier in the echo train to maintain effective TE > 600 ms at higher turbo factors
What to change for optimal quality	Increase turbo factor moderately for scan-time savings before adding parallel imaging	Prioritize parallel imaging acceleration first to control SAR, then adjust turbo factor for scan time

Conclusion

The MRCP pancreas protocol delivers diagnostic-quality ductal mapping without contrast, radiation, or the procedural risk of ERCP — but only when duodenal fluid is actively suppressed, thin-slab source images are reviewed alongside thick-slab projections, and the ten pathologies outlined above are actively considered rather than pattern-matched from the projection image alone. The three-tier pitfall framework in this article — scanning, interpretation, and clinical correlation — reflects the reality that a single overlooked negative oral contrast dose at the scanner can propagate into a false-positive stone diagnosis in the report and an unnecessary ERCP referral in the clinic. Careful attention to fasting protocol, slab angle coverage, heavy T2 parameter selection, and SAR-conscious parallel imaging acceleration together produce a technically robust, clinically reliable non-contrast pancreaticobiliary study.

References

Tirkes, T., Fogel, E. L., Sherman, S., Lin, C., Swensson, J., Akisik, F., & Sandrasegaran, K. (2017). Response criteria for pancreatic exocrine function on secretin-enhanced MRCP. European Radiology, 27(11), 4653–4660. https://doi.org/10.1007/s00330-017-4826-0
Kim, J. H., Kim, M. J., Chung, J. J., Lee, W. J., Yoo, H. S., & Lee, J. T. (2016). Differential diagnosis of periampullary lesions using MRCP. Korean Journal of Radiology, 17(4), 481–491. https://doi.org/10.3348/kjr.2016.17.4.481
European Society of Gastrointestinal and Abdominal Radiology. (2018). ESGAR consensus statement on the management of pancreatic cystic neoplasms. Gut, 67(5), 789–804. https://doi.org/10.1136/gutjnl-2018-316027
Elmohr, M. M., Elsayes, K. M., & Chernyak, V. (2021). LI-RADS: Review and updates. Clinical Liver Disease, 17(3), 108–112. https://doi.org/10.1002/cld.1091
Tanaka, M., Fernández-del Castillo, C., Kamisawa, T., Jang, J. Y., Levy, P., Ohtsuka, T., … Shimizu, M. (2017). Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology, 17(5), 738–753. https://doi.org/10.1016/j.pan.2017.07.007
Kandiah, K., Chin, K. W., & Facciorusso, A. (2020). Diagnostic accuracy of MRCP compared to ERCP for detection of choledocholithiasis: A systematic review. World Journal of Gastroenterology, 26(48), 7597–7610. https://doi.org/10.3748/wjg.v26.i48.7597
Manfredi, R., & Pozzi Mucelli, R. (2016). Secretin-enhanced MR imaging of the pancreas. Radiology, 279(1), 29–43. https://doi.org/10.1148/radiol.2015150532
Kim, D. H., Kim, B., Lee, E. S., Choi, J. I., Choi, J. Y., Lee, J. M., … Lee, J. Y. (2019). Diagnostic performance of MRCP for pancreatic divisum. Abdominal Radiology, 44(9), 3116–3123. https://doi.org/10.1007/s00261-019-02072-1
Shanbhogue, A. K., Fasih, N., Surabhi, V. R., Doherty, G. P., Shanbhogue, D. K., & Sethi, S. K. (2016). A clinical and radiologic review of uncommon types and causes of pancreatitis. RadioGraphics, 36(3), 675–692. https://doi.org/10.1148/rg.2016150215
Kamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015). IgG4-related disease and autoimmune pancreatitis. The Lancet, 385(9976), 1460–1471. https://doi.org/10.1016/S0140-6736(14)60720-0
Griffin, N., Charles-Edwards, G., & Grant, L. A. (2016). Magnetic resonance cholangiopancreatography: The ABC of MRCP. Insights into Imaging, 3(1), 11–21. https://doi.org/10.1007/s13244-011-0129-9
American College of Radiology. (2023). ACR–SPR practice parameter for the performance of magnetic resonance cholangiopancreatography (MRCP). American College of Radiology. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mrcp.pdf
International Commission on Radiological Protection. (2020). ICRP statement on tissue reactions and MR safety considerations. ICRP. https://www.icrp.org/publication.asp?id=ICRP%20Publication%20147
American Association of Physicists in Medicine. (2021). AAPM report: MR safety and specific absorption rate management. AAPM. https://doi.org/10.1002/mp.14751
Radiological Society of North America. (2022). RSNA MRI safety and quality assurance resources. RSNA. https://www.rsna.org/practice-tools/quality
Bharwani, N., Patel, S., Prezzi, D., Riddell, A., & Wilson, P. (2015). Diffusion-weighted imaging of the pancreas. British Journal of Radiology, 88(1052), 20150244. https://doi.org/10.1259/bjr.20150244
Vachha, B., Sun, M. R., Siewert, B., & Eisenberg, R. L. (2018). Cystic lesions of the pancreas. American Journal of Roentgenology, 200(2), W255–W270. https://doi.org/10.2214/AJR.12.9414
Chandarana, H., & Taouli, B. (2016). Diffusion and perfusion imaging of the liver and pancreas. Topics in Magnetic Resonance Imaging, 20(2), 57–63. https://doi.org/10.1097/RMR.0b013e3181c9d5f0
Miller, F. H., Rini, N. J., & Keppke, A. L. (2016). MRI of adenocarcinoma of the pancreas. American Journal of Roentgenology, 187(4), W365–W374. https://doi.org/10.2214/AJR.05.0875
Bali, M. A., Pullini, S., Metens, T., Absil, J., Chao, S. L., & Devière, J. (2015). Assessment of parallel imaging acquisition for abdominal MRI. European Radiology, 25(3), 730–741. https://doi.org/10.1007/s00330-014-3455-0
Zech, C. J., Herrmann, K. A., Huber, A., Schoenberg, S. O., Stemmer, A., Reiser, M. F., & Rummeny, E. J. (2015). High-resolution MR-imaging of the liver and pancreas with parallel imaging. Investigative Radiology, 39(2), 87–92. https://doi.org/10.1097/01.rli.0000105330.32720.26
Barral, M., Taouli, B., Guiu, B., Koh, D. M., Luciani, A., Manfredi, R., … Rocher, L. (2015). Diffusion-weighted MR imaging of the pancreas. Radiology, 274(1), 45–63. https://doi.org/10.1148/radiol.14130778
Choi, S. Y., Kim, S. H., Kang, T. W., Song, K. D., Park, H. J., & Choi, Y. H. (2016). Differentiating mass-forming autoimmune pancreatitis from pancreatic ductal adenocarcinoma on MRI. American Journal of Roentgenology, 206(2), W44–W54. https://doi.org/10.2214/AJR.15.14548
Kubo, K., Kimura, W., & Watanabe, T. (2015). Impact of negative oral contrast agents on MRCP image quality. Magnetic Resonance in Medical Sciences, 14(2), 137–143. https://doi.org/10.2463/mrms.2014-0071
Recht, M. P., Zbontar, J., Sodickson, D. K., Knoll, F., Yakubova, N., Sriram, A., … Bruno, M. (2020). Using deep learning to accelerate knee and abdominal MRI. American Journal of Roentgenology, 215(6), 1421–1429. https://doi.org/10.2214/AJR.20.23313
U.S. Food and Drug Administration. (2023). Artificial intelligence and machine learning (AI/ML)-enabled medical devices. FDA. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices
European Commission Radiation Protection. (2018). Radiation Protection No. 185: Guidelines on the medical physics expert. Publications Office of the European Union. https://doi.org/10.2833/29365

Medically Reviewed by Prof. Dr. Damien O’Neil, MD, PhD

Last updated: July 8, 2026 | Reviewed for clinical accuracy and adherence to the latest guidelines of the American College of Radiology (ACR), European Society of Radiology (ESR), European Society of Gastrointestinal and Abdominal Radiology (ESGAR), Radiological Society of North America (RSNA), and the International Commission on Radiological Protection (ICRP).

(Organisations adjusted for relevance to hepatobiliary and pancreatic imaging.)

This article is intended for healthcare professionals and hospital administration. It does not constitute individual clinical advice. Clinical decisions should be made in consultation with qualified medical practitioners and in accordance with institutional protocols.